Apogee Therapeutics, Inc. APGE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $60.82M+4.1% | $58.44M+7.9% | $54.18M-2.7% | $55.7M+20.1% | $46.39M-23.0% | ||
| $21.95M+11.9% | $19.61M+14.7% | $17.1M-2.1% | $17.46M+4.5% | $16.71M+6.8% | ||
| $82.77M+6.0% | $78.06M+9.5% | $71.28M-2.6% | $73.17M+16.0% | $63.1M-16.8% | ||
| -$82.77M-6.0% | -$78.06M-9.5% | -$71.28M+2.6% | -$73.17M-16.0% | -$63.1M+16.8% | ||
| $8.74M+0.1% | $8.73M+38.2% | $6.32M-11.5% | $7.14M-8.9% | $7.84M-9.7% | ||
| -$74.03M-6.8% | -$69.33M-6.7% | -$64.96M+1.6% | -$66.02M-19.5% | -$55.26M+17.8% | ||
| $79K+27.4% | $62K+1.6% | $61K-15.3% | $72K-13.3% | $83K+361% | ||
| -$74.11M-6.8% | -$69.39M-6.7% | -$65.02M+1.6% | -$66.1M-19.4% | -$55.34M+17.7% | ||
| -$1.06-2.9% | -$1.03+7.2% | -$1.11+1.8% | -$1.13-18.9% | -$0.95+20.2% | ||
| -$82.36M-6.1% | -$77.65M-9.6% | -$70.88M+2.6% | -$72.77M-15.7% | -$62.89M+17.0% | ||
| -$82.77M-6.0% | -$78.06M-9.5% | -$71.28M+2.6% | -$73.17M-16.0% | -$63.1M+16.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Apogee Therapeutics, Inc. profitable?
- Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.
- What is Apogee Therapeutics, Inc.'s earnings per share?
- Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does Apogee Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.